Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Experimental Therapy for Midgut Neuroendocrine Tumors Investigated in Clinical Trial


Clinical Trial

Midgut endocrine tumors are a rare form of cancer that affect the small intestine and the colon.

Share this!

March 1, 2017 | by Sarah Hand, M.Sc.

A new drug has been shown to improve progression-free survival in patients with rare midgut neuroendocrine tumors, according to researchers from Northwestern Medicine. The results of the global Phase III clinical trial were published in the New England Journal of Medicine.

Midgut endocrine tumors are a rare form of cancer that affect the small intestine and the colon. A somatostatin analogue is the first-line treatment for these types of tumors, however patients who experience disease progression have few options when it comes to alternative therapies. Patients with metastatic disease currently have an estimated 50 percent five-year survival rate.

The current study involved 229 patients with progressive midgut neuroendocrine tumors, who were randomly assigned to one of two treatment groups. Some patients received a high dose of the somatostatin analogue, octreotide long-acting repeatable (LAR), while others received the experimental drug, 177Lu-Dotatate.

177Lu-Dotatate is a peptide receptor radionuclide therapy (PRRT), capable of delivering a dose of radiation to the site of the tumor cells. The drug has not yet been approved by the FDA.

By the 20th month of the study, patients given the experimental 177Lu-Dotatate had a 65.2 percent estimated rate of progression-free survival. This was compared to just 10.8 percent for those patients given the standard of care, octreotide LAR.

While patients in the control group showed a treatment response rate of three percent, those patients given 177Lu-Dotatate showed an improved response rate of 18 percent. The study authors concluded that the disease progression and death risk for patients given the experimental therapy was 79 percent lower than those taking the first-line treatment.

“Northwestern Medicine is a major site for the treatment of neuroendocrine tumors,” said study co-author Dr. Al Benson, professor of Medicine in the Division of Hematology/Oncology. “Upon FDA approval, we look forward to being able to routinely offer our patients this therapy as an important advancement in care.”

Keywords: Clinical Trial, Cancer, Rare Disease


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.